Some studies have suggested that the prognosis of patients with high IL-33 content in CAFs in CCA patients is significantly better than that of patients with low IL-33 content in CAFs, suggesting that IL-33 is a marker of good prognosis in CCA and strengthening IL-33 in CAFs is a promising therapeutic direction 22. This evidence concerns the gene IL33 and cholangiocarcinoma.